Novavax said Monday that the COVID vaccine was more than 90% effective, including against variants, after a study of nearly 30,000 people in the United States and Mexico.
• Read also: Breastfeeding is recommended even with COVID-19
• Read also: Flight attendants’ revenge on COVID
And the American biotechnology company said in a statement that the vaccine “showed 100% protection against moderate and severe forms of the disease and 90.4% in general,” noting that it intends to obtain official marketing authorization by the end of the third quarter of 2021.
Novavax estimates that it will then be able to produce one hundred million doses per month, and then one hundred and fifty million by the end of the year.
“Novavax is close to meeting its goal of meeting the ongoing and critical global public health demand for new COVID vaccines,” said Stanley Erk, president of the company.
Novavax’s vaccine – NVX-CoV2373 with the official term – uses a technology different from that used in vaccines already widely authorized in the world: it is a so-called “subunit” vaccine, based on proteins that trigger a response. Immuno, virus-free.
Unlike other vaccines, it does not need to be stored at very cold temperatures, but only between 2 and 8 °C, which may facilitate its transportation and administration in countries at high risk.
More than two billion doses of COVID-19 vaccines have been administered worldwide, but disparities are very strong between countries.
On Friday, the richest countries promised to provide one billion doses of coronavirus vaccines to the poorest countries at the G7 summit.